| Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer GV Scagliotti, P Parikh, J Von Pawel, B Biesma, J Vansteenkiste, ... Journal of clinical oncology 26 (21), 3543-3551, 2008 | 4280 | 2008 |
| Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis PG Pappas, CMF Rotstein, RF Betts, M Nucci, D Talwar, JJ De Waele, ... Clinical infectious diseases 45 (7), 883-893, 2007 | 754 | 2007 |
| The growing burden of cancer in India: epidemiology and social context MK Mallath, DG Taylor, RA Badwe, GK Rath, V Shanta, CS Pramesh, ... The Lancet Oncology 15 (6), e205-e212, 2014 | 474 | 2014 |
| Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation J Cortes, JH Lipton, D Rea, R Digumarti, C Chuah, N Nanda, ... Blood, The Journal of the American Society of Hematology 120 (13), 2573-2580, 2012 | 176 | 2012 |
| Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3 … R Pettengell, B Coiffier, G Narayanan, FH de Mendoza, R Digumarti, ... The lancet oncology 13 (7), 696-706, 2012 | 157 | 2012 |
| Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non–small-cell lung cancer that … PM Parikh, A Vaid, SH Advani, R Digumarti, J Madhavan, S Nag, A Bapna, ... Journal of clinical oncology 29 (31), 4129-4136, 2011 | 99 | 2011 |
| Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non … DH Lee, JS Lee, SW Kim, J Rodrigues-Pereira, B Han, XQ Song, J Wang, ... European journal of cancer 49 (15), 3111-3121, 2013 | 89 | 2013 |
| Cancer research in India: national priorities, global results R Sullivan, RA Badwe, GK Rath, CS Pramesh, V Shanta, R Digumarti, ... The Lancet Oncology 15 (6), e213-e222, 2014 | 84 | 2014 |
| A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or … R Digumarti, Y Wang, G Raman, DC Doval, SH Advani, PK Julka, ... Journal of Thoracic Oncology 6 (6), 1098-1103, 2011 | 83 | 2011 |
| Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic‐phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors J Cortes, R Digumarti, PM Parikh, M Wetzler, JH Lipton, A Hochhaus, ... American journal of hematology 88 (5), 350-354, 2013 | 73 | 2013 |
| Epistatic interactions between loci of one-carbon metabolism modulate susceptibility to breast cancer SM Naushad, A Pavani, RR Digumarti, SR Gottumukkala, VK Kutala Molecular biology reports 38, 4893-4901, 2011 | 62 | 2011 |
| Targeted therapy for medullary thyroid cancer: a review SR Priya, CS Dravid, R Digumarti, M Dandekar Frontiers in oncology 7, 238, 2017 | 57 | 2017 |
| Aberrations in one-carbon metabolism induce oxidative DNA damage in sporadic breast cancer NS Mohammad, R Yedluri, P Addepalli, SR Gottumukkala, RR Digumarti, ... Molecular and cellular biochemistry 349, 159-167, 2011 | 56 | 2011 |
| Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up JE Cortes, HM Kantarjian, D Rea, M Wetzler, JH Lipton, L Akard, ... Cancer 121 (10), 1637-1644, 2015 | 55 | 2015 |
| Mitochondrial control region alterations and breast cancer risk: a study in South Indian population NR Tipirisetti, S Govatati, P Pullari, S Malempati, MK Thupurani, S Perugu, ... PloS one 9 (1), e85363, 2014 | 55 | 2014 |
| Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian … P Dorababu, N Nagesh, VG Linga, S Gundeti, VK Kutala, P Reddanna, ... European journal of clinical pharmacology 68, 379-387, 2012 | 50 | 2012 |
| Imatinib mesylate in early chronic phase chronic myeloid leukemia: Experience from a developing country S Rajappa, L Varadpande, T Paul, R Jacob, R Digumarti Leukemia & lymphoma 49 (3), 554-558, 2008 | 49 | 2008 |
| Barriers and challenges to global clinical cancer research B Seruga, A Sadikov, EL Cazap, LB Delgado, R Digumarti, NB Leighl, ... The Oncologist 19 (1), 61-67, 2014 | 47 | 2014 |
| Bavituximab plus paclitaxel and carboplatin for the treatment of advanced non-small-cell lung cancer R Digumarti, PP Bapsy, AV Suresh, GS Bhattacharyya, L Dasappa, ... Lung Cancer 86 (2), 231-236, 2014 | 46 | 2014 |
| Association of aberrations in one‐carbon metabolism with molecular phenotype and grade of breast cancer SM Naushad, A Pavani, Y Rupasree, S Divyya, S Deepti, RR Digumarti, ... Molecular Carcinogenesis 51 (S1), E32-E41, 2012 | 46 | 2012 |
Purvish M ParikhMahatma Gandhi Medical College and Hospital, JaipurVerified email at purvishparikh.com
